サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1738673

ジフテリア・破傷風・百日咳（DTaP）ワクチンの世界市場規模：製品タイプ別、年齢層別、エンドユーザー別、地域範囲別、予測

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size By Product Type (DTaP-IPV, TD and Tdap-hEPb-IPV), By Age Group (Adult, Pediatrics), By End-User (Hospitals, Clinics and Vaccination Centers), By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
ジフテリア・破傷風・百日咳（DTaP）ワクチンの世界市場規模：製品タイプ別、年齢層別、エンドユーザー別、地域範囲別、予測
出版日: 2025年05月02日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ジフテリア・破傷風・百日咳（DTaP）ワクチンの市場規模・予測

ジフテリア・破傷風・百日咳（DTaP）ワクチンの市場規模は、2024年に71億8,000万米ドルと評価され、2026年から2032年にかけてCAGR 7.3%で成長し、2032年には67億5,000万米ドルに達すると予測されています。

  • ジフテリア・破傷風・百日咳（DTaP）ワクチンは、ジフテリア、破傷風、百日咳の3つの感染症から身を守る混合ワクチンです。生涯を通じて接種することが推奨されています。これらの予防接種は通常、定期予防接種プログラムの一環として子供たちに行われます。
  • 破傷風、百日咳、ジフテリアから子供を守るには、DTaPワクチン接種を受けなければならないです。特に幼児の場合、多くの病気が重篤化する可能性があります。これらの病気に対する最善の予防策は、予防接種です。
  • 政府の予防接種プログラム、予防接種意識の高まり、ワクチン技術の発展は、DTaPワクチン市場を牽引する理由の一部です。
  • 国立医学図書館によると、DTaPワクチンは6週間から6歳までの子供に注射され、DTaPに対する免疫を与えます。特定のワクチンで予防可能な病気に罹患した場合、致命的な結果や生命を脅かす合併症が発生する可能性があります。

ジフテリア・破傷風・百日咳（DTaP）ワクチンの世界市場ダイナミクス

ジフテリア・破傷風・百日咳（DTaP）ワクチン市場を形成している主な市場力学は以下の通りです：

主な市場促進要因

  • 小児ワクチン接種の増加：DTaPワクチン接種を受ける子どもの数は、世界の出生率の上昇と発展途上国における小児予防接種プログラムへの関心の高まりにより、著しく増加しています。
  • DTaPワクチンの研究開発活動：製薬会社は、新しいDTaPワクチンの研究開発を続けています。こうした開発には、副作用の少ないワクチンや、百日咳、破傷風、ジフテリアに加え、多くの病気に対する予防効果を持つ混合ワクチンなどがあります。
  • 予防接種に対する意識の高まり：公衆衛生プログラムや教育キャンペーンは、特に発展途上国において、予防接種の価値に対する知識を大いに高めています。より多くの親が、推奨されるスケジュールに従って子どもに予防接種を受けることを選択しています。
  • 政府の取り組みと資源：予防接種をより広く普及させるため、いくつかの政府は強力な予防接種プログラムを実施し、財政援助を行っています。特に低・中所得国ではその傾向が強いです。

主な課題

  • 高いワクチン開発費：新しいDTaPワクチンの開発、製造、販売には多額の費用がかかります。そのため、この分野に投資する企業が減少し、技術革新の妨げになる可能性があります。
  • 誤った情報とワクチンへのためらい：ネット上で広まる誤った情報やワクチン接種へのためらいの結果、親が子供へのワクチン接種を延期したり拒否したりする可能性があります。その結果、疾病の発生が回避され、予防接種率が全体的に低下する可能性があります。
  • サプライチェーンの問題：複雑な製造工程、入手困難な原材料、複雑な流通計画などのために、メーカーが一部のDTaPワクチン接種を中止したり、製造に問題が生じたりすることで、短期間の供給不足が発生することがあります。このような場合、予防接種のスケジュールに支障をきたし、子供の予防が遅れる可能性があります。
  • 新興の疾患株：DTaPのワクチン成分である百日咳は変化を続けており、ワクチン接種による防御を克服する可能性のある新型が出現しています。新型株に対するワクチン効果を維持するためには、疾病疫学の変化を追跡し、ワクチン製剤を適切に変更するための継続的な研究開発とモニタリングが不可欠です。

主要動向：

  • 世界のパンデミックへの備え：COVID-19の流行は、パンデミックへの備えとワクチン接種の重要性を浮き彫りにしました。世界のワクチン流通網を改善し、ワクチン製造を強化し、ワクチンサプライチェーンを強化するため、政府、ヘルスケア・システム、ワクチン製造業者は研究開発とインフラ整備に投資しています。予防接種インフラ全体を強化し、将来の潜在的な流行に備えることで、こうした取り組みがDTaPワクチン市場を後押しするはずです。
  • AIとその他の先端技術：DTaPワクチンの開発は、人工知能やその他の先端技術の活用にますます依存しています。AIは、研究を迅速化し、ワクチン設計やワクチン製造手順を強化する可能性を秘めています。
  • 新興市場における需要の高まり：1回の接種で複数の病気を予防できる予防接種への関心が高まっています。その結果、青少年が必要とする予防接種の回数は全体的に少なくなり、ワクチンの接種完了率は上昇します。DTaPにB型肝炎とB型インフルエンザ予防を加えた5種混合ワクチン。
  • 新しいワクチン開発の重視：新しいDTaPワクチンの研究開発が続けられています。これには、効力の増強、免疫の持続時間の延長、副作用の軽減などが含まれます。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション
  • 調査手法

第2章 エグゼクティブサマリー

  • 主な調査結果
  • 市場概要
  • 市場ハイライト

第3章 市場概要

  • 市場規模と成長の可能性
  • 市場動向
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • ポーターのファイブフォース分析

第4章 ジフテリア・破傷風・百日咳（DTaP）ワクチン市場：製品タイプ別

  • DTaP-IPVワクチン
  • TD
  • Tdap-hEPb-IPVワクチン

第5章 ジフテリア・破傷風・百日咳（DTaP）ワクチン市場：年齢層別

  • 成人
  • 小児

第6章 ジフテリア・破傷風・百日咳（DTaP）ワクチン市場：エンドユーザー別

  • 病院
  • 診療所
  • 予防接種センター

第7章 地域別分析

  • 北米
  • 米国
  • カナダ
  • メキシコ
  • 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • チリ
  • 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第8章 市場力学

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • COVID-19の市場への影響

第9章 競合情勢

  • 主要企業
  • 市場シェア分析

第10章 企業プロファイル

  • GLAXOSMITHKLINE PLC（GSK）
  • Sanofi Pasteur
  • GlaxoSmithKline
  • SERUM INSTITUTE OF INDIA PVT. LTD
  • Protein Sciences Corporation
  • Novartis AG
  • Seqirus（formerly CSL Behring）
  • Merck Sharp & Dohme Corp（MSD）
  • Astellas Pharma Inc
  • Pfizer Inc
  • Johnson & Johnson.

第11章 市場の展望と機会

  • 新興技術
  • 今後の市場動向
  • 投資機会

第12章 付録

  • 略語リスト
  • 出典と参考文献
目次
Product Code: 35819

Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market Size And Forecast

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market size was valued at USD 7.18 Billion in 2024 and is projected to reach USD 6.75 Billion by 2032, growing at a CAGR of 7.3% from 2026 to 2032.

  • The Diphtheria, Tetanus, and Pertussis (DTaP) vaccine is a combination vaccine that provides protection against three infectious diseases: diphtheria, tetanus, and pertussis (whooping cough). Even the booster shots are advised throughout life. These vaccinations are normally given to children as part of regular immunization programs.
  • To protect kids from tetanus, pertussis, and diphtheria, they must receive the DTaP vaccinations. Particularly in young children, many illnesses have the potential to be serious. The best protection against these illnesses is vaccination.
  • Government immunization programs, rising vaccination awareness, and developments in vaccine technology are some of the reasons driving the market for DTaP vaccines.
  • According, to National Library of Medicine DTaP vaccine is injected to the 6 weeks to 6 years of age of children's it gives immunity against DTaP. People who are dependent to certain vaccine-preventable illnesses may experience fatal consequences or even life-threatening complications.

Global Diphtheria, Tetanus, and Pertussis Vaccine Market Dynamics

The key market dynamics that are shaping the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market include:

Key Market Drivers:

  • Rise in Children Vaccination: The number of children receiving DTaP vaccinations is significantly rising due to rising global birth rates and increased attention on childhood immunization programs in developing nations.
  • Research and Development Activities in DTaP Vaccines: Pharmaceutical companies are continually investigating and creating new and enhanced DTaP vaccines. These developments can include vaccines with fewer side effects or combination of doses that offer protection against many diseases in addition to pertussis, tetanus, and diphtheria.
  • Growing Awareness Regarding Vaccinations: Public health programs and educational campaigns, especially in developing nations, are greatly raising knowledge of the value of vaccinations. More parents are choosing to vaccinate their children in accordance with suggested timelines.
  • Government Initiatives and Resources: To make these vaccinations more widely available, several governments are putting in place robust immunization programs and providing financial assistance. Particularly in low- and middle-income nations is this true.

Key Challenges:

  • High Cost of Vaccine Development: The process of investigating, creating, and releasing new DTaP vaccinations is costly. This may reduce the number of businesses making investments in this area could hinder innovation.
  • Misinformation and Vaccine hesitation: Parents may decide to postpone or refuse to vaccinate their children as a result of misinformation spreading online and vaccine hesitation. This may lead to avoid disease outbreaks and lower immunization rates overall.
  • Supply Chain Issues: Manufacturers discontinuance of some DTaP vaccinations or production problems because of things like complicated manufacturing processes, difficult to find raw materials, and complicated distribution plans might occasionally result in brief shortages of supplies. This may interfere with immunization schedules and postpone kid protection.
  • Emerging Disease Strains: As pertussis, a vaccine component in the DTaP, continues to change, new strains of the disease that might overcome vaccination-induced protection are appearing. In order to maintain vaccine efficacy against developing strains, it is essential to conduct ongoing research and monitoring to track changes in disease epidemiology and modify vaccine formulations appropriately.

Key Trends:

  • Worldwide Pandemic Preparedness: The COVID-19 outbreak has highlighted the significance of being ready for pandemics and having vaccinations in place. To improve global vaccine distribution networks, boost vaccine manufacturing, and strengthen vaccine supply chains, governments, healthcare systems, and vaccine manufacturers are investing in R&D and infrastructure. By strengthening the entire vaccination infrastructure and preparing for potential future epidemics, these initiatives should help the DTaP vaccine market.
  • AI and Other Advanced Technologies: The development of the DTaP vaccine is increasingly reliant on the use of artificial intelligence and other advanced technologies. AI has the potential to expedite research, enhance vaccine design, and vaccine production procedures.
  • Growing Demand in Emerging Markets: People are becoming more and more interested in emerging of vaccinations, which offer multi-disease protection in a single dose. As a result, a youngster requires fewer vaccinations overall, and vaccine completion rates rise. Pentavalent vaccinations, which combine DTaP with protection against Hepatitis B and Haemophilus influenza type B.
  • Emphasis on Developing New Vaccines: Research and development are continuing to produce new DTaP vaccines with enhanced qualities. This covers vaccinations with increased potency, immunity that lasts longer, or reduced adverse effects.

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Diphtheria, Tetanus, and Pertussis (DTaP) vaccine market:

North America:

  • The duration of the forecast period, North America is anticipated to lead the market. This is explained by the fact that North America has a 34.8% market share and is home to many important industry players. Prominent industry participants, including Sanofi, AJ Vaccines A/S, GSK plc, Merck & Co., Inc., and others, are well-represented in this area.
  • Due to their extensive public health awareness and well-established pediatric immunization programs, North American countries often have high vaccination rates.
  • Patients in North America have greater access to DTaP vaccines because to the generally favorable reimbursement policies of both government and insurance provider providers.

Europe:

  • The duration of the projection period, the Europe area is anticipated to rank second in size. Because skin conditions are becoming more common in Europe. For example, a National Library of Medicine report from March 2022 states that 185,103,774 people in Europe had a dermatological ailment or disease in 2021.
  • Due to prevalence of dermatological diseases Europe contain DTaP vaccine which offers protection against bacterial illnesses such as pertussis, tetanus, and diphtheria. On the other hand, a variety of skin disorders known as dermatological illnesses are not brought on by these microorganisms.
  • Numbers of European nations have firmly developed healthcare systems with strong immunization program infrastructure. European governments have implemented robust immunization policies and provided financial support, thereby facilitating the accessibility of DTaP vaccinations. These reasons contribute to the high immunization rates for DTaP vaccinations in many European nations.

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market: Segmentation Analysis

The Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market is segmented on the basis of Product Type, Age Group, End User, And Geography.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By Product Type

  • DTaP-IPV
  • TD
  • Tdap-hEPb-IPV

Based on the Product Type, the market is distributed into DTaP-IPV, TD and Tdap-hEPb-IPV and Others. Due to increased DTaP vaccine usage and new product launches, the DTaP vaccine segment is anticipated to lead the diphtheria vaccine market throughout the forecast period.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By Age Group

  • Adult
  • Pediatrics

Based on Age Group, the market is segmented into Adult and Pediatrics. During the projection period, the pediatrics category is anticipated to dominate the market, primarily because major players in the industry have increased their research and development expenditure.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By End-User

  • Hospitals
  • Clinics
  • Vaccination Centers

Based on End-User, the market is fragmented into Hospitals, Clinics and Vaccination Centers. The course of the projection period, hospitals are anticipated to dominate the market. This is due to an increase in government measures to open hospital novel wards for the prevention of diphtheria.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Geography, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is likely to remain a major player in the DTaP vaccine market in the foreseeable future, but the competitive landscape may evolve as other regions develop their markets.

Key Players

  • The "Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GLAXOSMITHKLINE PLC (GSK), Sanofi Pasteur, GlaxoSmithKline, SERUM INSTITUTE OF INDIA PVT. LTD, Protein Sciences Corporation, Novartis AG, Seqirus (formerly CSL Behring), Merck Sharp & Dohme Corp (MSD), Astellas Pharma Inc, Pfizer Inc, Johnson & Johnson. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Recent Developments
  • In December 2022, the 6-in-1 Hexavalent Vaccine development partnership between BIONET-ASIA, a vaccine manufacturing business, and Pharmaniaga Berhad, a pharmaceutical company based in Malaysia, was announced, with the help of the vaccine. Malaysian healthcare professionals would have the choice to vaccinate children against six common childhood illnesses, including hepatitis B (Hep-B), poliomyelitis (IPV), pertussis (aP), tetanus (TT), and diphtheria (DT).
  • In June 2022 , Global pharmaceutical company GSK plc revealed that it has invested over US$ 1.2 billion to speed up research and development (R&D) aimed at creating vaccines and medications to treat and prevent HIV (through ViiV Healthcare), malaria, tuberculosis, neglected tropical diseases (NTDs), and diphtheria.
  • In October 2020, a vaccine manufacturer named BIONET-ASIA declared that the Phase-II clinical trials for Tetanus, Diphtheria, and Pertussis (In Children, Prevention) were concluded in Thailand.

TABLE OF CONTENTS

1. Introduction

  • Market Definition
  • Market Segmentation
  • Research Methodology

2. Executive Summary

  • Key Findings
  • Market Overview
  • Market Highlights

3. Market Overview

  • Market Size and Growth Potential
  • Market Trends
  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Porter's Five Forces Analysis

4. Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market, By Product Type

  • DTaP-IPV
  • TD
  • Tdap-hEPb-IPV

5. Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market, By Age Group

  • Adult
  • Pediatrics

6. Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market, By End-User

  • Hospitals
  • Clinics
  • Vaccination Centers

7. Regional Analysis

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Latin America
  • Brazil
  • Argentina
  • Chile
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

8. Market Dynamics

  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Impact of COVID-19 on the Market

9. Competitive Landscape

  • Key Players
  • Market Share Analysis

10. Company Profiles

  • GLAXOSMITHKLINE PLC (GSK)
  • Sanofi Pasteur
  • GlaxoSmithKline
  • SERUM INSTITUTE OF INDIA PVT. LTD
  • Protein Sciences Corporation
  • Novartis AG
  • Seqirus (formerly CSL Behring)
  • Merck Sharp & Dohme Corp (MSD)
  • Astellas Pharma Inc
  • Pfizer Inc
  • Johnson & Johnson.

11. Market Outlook and Opportunities

  • Emerging Technologies
  • Future Market Trends
  • Investment Opportunities

12. Appendix

  • List of Abbreviations
  • Sources and References